Scientific Glossary

An agonist mimics or amplifies the effect of the body's natural signaling molecules. Full agonists produce the maximum possible receptor activation. Partial agonists activate the receptor but produce a submaximal response even at saturation. The distinction matters in research because partial agonists can act as functional antagonists by occupying receptors without fully activating them. GLP-1 receptor agonists like semaglutide are full agonists at the GLP-1 receptor.

Antagonists occupy receptor binding sites competitively (reversible) or non-competitively (irreversible), blocking the receptor's activation. Unlike agonists, they do not trigger a response — they prevent one. Competitive antagonists can be overcome by increasing agonist concentration; non-competitive antagonists cannot. In peptide research, understanding the antagonist/agonist distinction is critical for interpreting mechanism studies that use receptor blockers to confirm which pathway a peptide acts through.

Cyclical protocols are common in peptide research design. Examples: Epithalon studied in 10-day cycles with 1-4 month gaps; GHRPs studied with on/off patterns to avoid GH receptor desensitization. The scientific rationale involves receptor recycling, restored sensitivity, and avoiding chronic suppression of endogenous production. Research cycle lengths vary widely — some literature uses 4-weeks-on/4-weeks-off, others use 3 months on with 1 month off. Protocol design should reference specific published study parameters for each compound.

Receptor desensitization involves several mechanisms: phosphorylation of the receptor by GRKs (GPCR kinases), recruitment of beta-arrestins which sterically block G protein coupling, and receptor internalization (endocytosis). Different from pharmacokinetic tolerance (metabolism increases). Desensitization is time-dependent — short intervals between doses more likely to produce it. Understanding desensitization kinetics is critical for research protocol design, particularly for compounds targeting GPCRs like GLP-1R, ghrelin receptor, and melanocortin receptors.

GHRPs are synthetic peptides that act on the ghrelin receptor (GHSR-1a) to stimulate GH release. Unlike GHRH, GHRPs do not require GHRH activity — they activate a complementary and synergistic pathway. When GHRH and GHRP are combined, GH pulses are dramatically amplified (2-10x in some studies) compared to either alone. This synergy is the scientific basis for GHRH+GHRP combination research protocols. Examples: ipamorelin, GHRP-6, hexarelin.

GPCRs are transmembrane receptors that couple to intracellular G proteins upon ligand binding. The G protein then activates secondary messengers (cAMP, IP3, DAG) to produce cellular responses. The GLP-1 receptor, ghrelin receptor (GHSR), melanocortin receptors (MC1R-MC5R), GnRH receptor, and KISS1R are all GPCRs. Over 30% of approved drugs target GPCRs, highlighting their pharmaceutical importance. GPCR activation and desensitization mechanisms are critical for understanding peptide pharmacology.

The melanocortin system involves 5 receptor subtypes with distinct tissue distributions: MC1R (pigmentation in melanocytes), MC2R (ACTH receptor in adrenal glands), MC3R (energy balance in hypothalamus), MC4R (food intake, sexual function, energy), MC5R (exocrine glands). PT-141 (bremelanotide) acts on MC3R and MC4R to produce sexual arousal responses — the first CNS-targeted sexual dysfunction peptide. Melanotan II also targets this system with broader receptor engagement. MC4R agonism is intensely studied for obesity treatment.

No compound is perfectly specific. Off-target effects can be beneficial (an anti-diabetes drug that also protects the heart, as seen with GLP-1 agonists) or adverse. Understanding off-target profiles requires systematic receptor binding studies and broad safety pharmacology. For research peptides, off-target effects are often unknown or understudied because comprehensive receptor panels aren't typically part of early preclinical work. This is a key limitation cited when discussing research peptides' overall safety and effect profiles.

Pharmacodynamics is the companion to pharmacokinetics. While PK asks "what does the body do to the drug?", PD asks "what does the drug do to the body?" Key PD parameters: Emax (maximum effect), EC50 (concentration producing 50% maximum effect), receptor binding affinity (Kd, Ki), and the dose-response relationship. Understanding PD requires knowing which receptors a compound engages, with what affinity, and what the downstream signaling consequences are. PK/PD modeling combines both to predict effects over time.

When receptors are continuously exposed to high levels of an agonist, cells often compensate by reducing the number of receptors on the cell surface (downregulation) or making existing receptors less responsive (desensitization). This is why research studies often use pulsatile or cyclical administration rather than continuous exposure. For example, GHRH receptors downregulate with continuous GHRH stimulation — this is why pulse administration is studied more than continuous infusion for GH secretagogues.

Receptor selectivity is critical for predicting a compound's effect profile. Ipamorelin is considered "selective" among GHRPs because it stimulates GH release with minimal cortisol or prolactin elevation — unlike GHRP-6 or hexarelin. Semaglutide is highly selective for GLP-1R over GLP-2R, GIP-R, and glucagon receptor. Tirzepatide intentionally lacks selectivity between GIP-R and GLP-1R. Selectivity is quantified by affinity ratios (Ki for target receptor vs. Ki for off-target receptors). Higher selectivity generally correlates with more predictable effect profiles.

Washout periods eliminate carryover effects between study periods. Duration should be at least 5 half-lives of the compound to ensure >97% clearance. For semaglutide (7-day t½), a full washout requires ~5 weeks. For short half-life peptides (BPC-157, ipamorelin), washout is rapid. Crossover trial designs require carefully calculated washout periods between each treatment phase. In research cycles, washout periods also serve the biological function of restoring receptor sensitivity and endogenous production.